Zenidatamab for injection (zanidatamab-hrii)-Who is the manufacturer of Ziihera?

Zenidatamab-hrii for injection (zanidatamab-hrii)-Ziihera is an innovative drug jointly developed by Jazz Pharmaceuticals and BeiGene, Ltd. The molecular design and development of this drug was initially performed by Zymeworks under a licensing agreement with Zymeworks, marking the successful application of this technology platform. Zanidatamab is the world's first and only bispecific antibody approved for HER2-positive biliary tract cancer (BTC), and its clinical application is of great significance.

Ziihera's unique mechanism of action is that it is a bispecific HER2-directed antibody that binds to two extracellular sites of the HER2 receptor simultaneously. This design makes Zanidatamab-HRII more targeted and effective in treating tumors. When Zanidatamab binds to HER2, it triggers the internalization process, leading to a reduction in the number of HER2 receptors on the surface of tumor cells, thereby inhibiting the growth of tumor cells. In addition, Zanidatamab also induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). These mechanisms work together to inhibit tumor cells in vitro and in vivo, ultimately leading to cell death.

In terms of clinical application,Ziihera is approved by the FDA for the treatment of adult patients with unresectable or metastatic HER2-positive biliary tract cancer who have received other therapies. The approval was based on clinical trial results showing the drug's potential to control disease progression and improve patient survival. Because of Ziihera's unique mechanism and its ability to target HER2, it provides a new treatment option for patients with HER2-positive tumors, especially when existing therapies are ineffective.

Reference materials:https://ir.zymeworks.com/news-releases/news-release-details/fda-grants-us-approval-ziiherar-zanidatamab-hrii-treatment/